Get the Stockscreener App
87.18
1.23%
-1.05
Overview
News
Price History
Option Chain
Financials
Why ALC Down?
Discussions
Forecast
Dividend History
Alcon Inc stock is traded at $87.18, with a volume of 312.00K.
It is down -1.23% in the last 24 hours and down -5.06% over the past month.
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls one fourth of the U.S. contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
See More
Previous Close:
$88.23
Open:
$87.44
24h Volume:
312.00K
Relative Volume:
0.40
Market Cap:
$43.01B
Revenue:
$9.76B
Net Income/Loss:
$1.16B
P/E Ratio:
121.08
EPS:
0.72
Net Cash Flow:
$665.00M
1W Performance:
-0.11%
1M Performance:
-5.06%
6M Performance:
-2.78%
1Y Performance:
+14.89%
1-Day Range:
$86.81
$87.56
1-Week Range:
$86.81
$89.14
52-Week Range:
$71.45
$101.10
Alcon Inc Stock (ALC) Company Profile
Name
Alcon Inc
Sector
Industry
Phone
-
Address
-
Compare ALC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALC
Alcon Inc
|
87.22 | 43.01B | 9.76B | 1.16B | 665.00M | 2.34 |
|
ISRG
Intuitive Surgical Inc
|
535.92 | 193.58B | 7.87B | 2.24B | 586.00M | 6.22 |
|
BDX
Becton Dickinson Co
|
222.22 | 64.01B | 20.18B | 1.71B | 3.07B | 5.94 |
|
RMD
Resmed Inc
|
248.18 | 35.98B | 4.81B | 1.11B | 1.35B | 7.55 |
|
WST
West Pharmaceutical Services Inc
|
318.49 | 23.43B | 2.88B | 499.60M | 321.60M | 6.74 |
Alcon Inc Stock (ALC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-12-24 | Reiterated | Needham | Buy |
| Oct-10-24 | Upgrade | Redburn Atlantic | Sell → Neutral |
| Sep-10-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jul-15-24 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| May-15-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-10-24 | Initiated | Goldman | Buy |
| Mar-14-24 | Initiated | RBC Capital Mkts | Sector Perform |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Jan-23-24 | Initiated | Bernstein | Outperform |
| Dec-18-23 | Downgrade | Redburn Atlantic | Neutral → Sell |
| Dec-12-23 | Initiated | Stifel | Buy |
| Dec-04-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Aug-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| May-10-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-01-23 | Upgrade | Societe Generale | Sell → Hold |
| Dec-22-22 | Initiated | Mizuho | Buy |
| Nov-17-22 | Downgrade | Societe Generale | Hold → Sell |
| Aug-11-22 | Downgrade | Societe Generale | Buy → Hold |
| May-13-22 | Resumed | Credit Suisse | Outperform |
| May-12-22 | Upgrade | Stephens | Equal-Weight → Overweight |
| Apr-08-22 | Initiated | Needham | Buy |
| Mar-11-22 | Initiated | BofA Securities | Buy |
| Jan-18-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jan-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-01-21 | Initiated | Oppenheimer | Perform |
| Jul-14-21 | Initiated | Deutsche Bank | Buy |
| May-06-21 | Upgrade | Citigroup | Sell → Neutral |
| Mar-22-21 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-12-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-06-20 | Downgrade | Citigroup | Neutral → Sell |
| Jul-06-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-08-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-26-20 | Upgrade | Argus | Hold → Buy |
| Mar-24-20 | Upgrade | Societe Generale | Sell → Hold |
| Mar-13-20 | Upgrade | UBS | Neutral → Buy |
| Mar-05-20 | Initiated | Citigroup | Neutral |
| Feb-26-20 | Upgrade | Berenberg | Hold → Buy |
| Jan-08-20 | Initiated | Argus | Hold |
| Oct-29-19 | Initiated | Stephens | Equal-Weight |
| Aug-21-19 | Reiterated | BofA/Merrill | Neutral |
| Jun-24-19 | Initiated | SVB Leerink | Mkt Perform |
| Jun-14-19 | Initiated | BTIG Research | Neutral |
| May-10-19 | Initiated | Robert W. Baird | Outperform |
| May-02-19 | Initiated | Credit Suisse | Outperform |
View All
Alcon Inc Stock (ALC) Latest News
Dry Eye Disease Market Outlook to 2034: Insights into Epidemiology, Pipeline Developments, and Recent Regulatory Approvals by DelveInsight | Featuring Major Players Like Alcon, Allysta Pharmaceuticals - The Globe and Mail
Ocular Trauma Devices Market Is Booming Worldwide with Alcon, Zeiss, Santen - openPR
India Contact Lenses Market Forecasts and Company Analysis Report 2023-2024 & 2032 Featuring Bausch & Lomb, Alcon Laboratories, J&J, Cooper Vision, Carl Zeiss, Hoya Medical, GKB Ophthalmic and Omni - Yahoo Finance
Ophthalmology Devices Market Analysis Report 2025-2030: Industry Trends, Market Shares and Competitive Strategies - GlobeNewswire Inc.
What Analyst Projections for Key Metrics Reveal About Alcon (ALC) Q3 Earnings - MSN
Alcon Q3 Earnings Top Estimates, Margins Up, Stock Gains in Afterhours - MSN
Impressive Earnings May Not Tell The Whole Story For Alcon (VTX:ALC) - Yahoo Finance
Alcon (ALC) is a Top-Ranked Value Stock: Should You Buy? - Yahoo Finance
Most Venture Investors Want Their Startups to Go Public. Not This One. - The Wall Street Journal
Alcon Laboratories is considering a major $100M expansion of its Fort Worth campus - AOL
Results: Alcon Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts - Yahoo Finance
Reiterate Overweight on Alcon with $107 target post 3Q results - Investing.com
Alcon Inc. (NYSE:ALC) Q3 2024 Earnings Call Transcript - Insider Monkey
Alcon shares maintain Buy rating and $107 target post-results By Investing.com - Investing.com Australia
Earnings call: Alcon reports solid Q3 growth, updates full-year guidance - Investing.com UK
Reiterate Overweight on Alcon with $107 target post 3Q results By Investing.com - Investing.com Nigeria
Alcon: Q3, Slight Guidance Cut Is Not Something Structural - Seeking Alpha
Alcon Third Quarter 2024 Earnings: EPS Beats Expectations - Yahoo Finance
3 Focus Stocks: Alcon, Up Fintech, and Monolithic Power Systems - Baystreet.ca
ALCON : Q3 miss and an outlook downgrade should not be seen as worrisome - Marketscreener.com
Pharmaceuticals: Alcon records lower growth in the third quarter | blue News - bluewin E-Mail
Alcon cuts 2024 forecasts, as slow US hits surgical unit - MSN
Alcon Lowers Financial Outlook After US Sales Slump - Finimize
Alcon trims revenue forecast - 69News WFMZ-TV
Alcon shares maintain Buy rating and $107 target post-results - Investing.com
Alcon Reports Solid Third-Quarter 2024 Results, including Double-Digit Earnings Growth and Record Cash Generation - sharewise
Alcon Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Alcon (ALC) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Alcon falls 6% as company trims 2024 sales outlook - MSN
Alcon Posts Higher 3Q Sales and Profit, Lowers 2024 Sales View - MarketWatch
Alcon’s Strong Q3 2024 Results Boost Investor Confidence - TipRanks
Cell therapy startup's IPO plans thrown in limbo amid legal spat with investor Alcon - Endpoints News
Subdued Growth No Barrier To Alcon Inc.'s (VTX:ALC) Price - Simply Wall St
Tarsus Pharmaceuticals seesaws amid report Alcon interest has cooled - MSN
Alcon focuses on bringing high-quality innovations to China to address different consumers’ needs - Global Times
Alcon launches Precision7, a 1-week silicone hydrogel replacement contact lens - Healio
Customer-centricity takes the spotlight during clinical transformation - Medical Device Network
Alcon Announces the U.S. Launch of PRECISION®, the Only One-Week Replacement Contact Lens - Marketscreener.com
GLOBALink | CIIE's spillover effect boosts innovations, digitalization: Alcon China president - Xinhua
Alcon supporting optometry students through educational grant - Insight
Global Dry Eye Disease Treatment Market Projected to Cross USD 9 Billion by 2030 | DelveInsight - PR Newswire
Alcon Inc. (ALC): Among UBS’ Top Tech Based Disruptive Stocks For 2030 - Insider Monkey
Alcon Receives Prestigious Export Achievement Award - The BRAKE Report
Alcon (VTX:ALC) Might Have The Makings Of A Multi-Bagger - Simply Wall St
Alcon Inc. receives Investment Bank Analyst Rating Update By Investing.com - Investing.com
World Council of Optometry and Alcon Launch ‘WCO Alcon Dry Eye Wheel’ Tool in Spanish - Vision Monday
Alcon Singapore Elevates Associate Experience with Inspiring Engagement Programs - Yahoo Finance
Zeiss Callisto Digital Alignment System Superior to Alcon for Toric IOL Implantation - Physician's Weekly
Open-Angle Glaucoma Therapeutics Market Expecting Huge Demand - openPR
Novartis To Buy Nestlé's 52% Stake In Alcon For $28.1 BlnUpdate - RTTNews
SightMD Introduces Advanced Alcon Topo-Guided Wavelight® Laser with Contoura® Vision to Enhance LASIK Eye Surgery Options - PR Web
Alcon Inc Stock (ALC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.34%
1.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):